Global Gene Delivery Systems Market Size (2024 - 2029)

Gene Delivery System Market Analysis

The gene delivery systems market is anticipated to register a CAGR of 7.3% over the forecast period.

COVID-19 had a significant impact on the gene delivery systems market. For instance, as per an article published by Drug Discovery Today in October 2021, the research, production, clinical development, and market introduction of cell and gene therapy (CGTs) for diseases unrelated to COVID-19 have all been significantly disrupted because of the COVID-19 pandemic. For CGTs with indications for rare, life-threatening conditions, telemedicine is found to be a potent tool to reduce the loss of follow-ups in clinical trials. Furthermore, Prime Therapeutics launched its PreserveRx gene therapy reinsurance product in the initial phase of COVID-19's spread across the United States to support the only two gene therapies available at the time, Luxturna and Zolgensma. Prime coordinated contracting with the manufacturer Novartis Gene Therapy for value-based outcomes in 2021. Further, in August 2021, Novartis launched a new phase three study to expand the use of Zolgensma, the one-time therapy at USD 2.1 million per patient treatment after the U.S. regulator lifted restrictions. Following these initiatives taken by the market players during the pandemic, the market has recovered and is expected to show robust growth over the forecast period.

The significant factors contributing to the market growth are the rising incidence and prevalence of chronic diseases and the increasing technological advancement in drug delivery. Some leading chronic diseases in developed countries, such as the United States, are cardiovascular diseases, infectious diseases, cancer, diabetes, and others. For instance, as per a 2023 update from the American Cancer Society, 2 million new cancer cases are likely to be diagnosed in the United States in 2023. Additionally, an article published by the National Library of Medicine, in June 2021 mentioned that in Spain, the reported prevalence of cardiovascular diseases among patients with type 2 diabetes ranged from 6.9% to 40.8% in 2021. According to the same source, the prevalence of coronary heart disease ranged from 4.7% to 37%, stroke from 3.5% to 19.6%, peripheral artery disease from 2.5% to 13.0%, and heart failure from 4.3% to 20.1%. The high incidence of chronic diseases is likely to increase the demand for substantial diagnostic procedures, which drives the market.

Moreover, the increasing ongoing research and development in the field of genomics worldwide are also expected to contribute to the market growth over the forecast period. For instance, in May 2022, Pell Bio-Med Technology Co., Ltd., sponsored a clinical study to evaluate the safety and efficacy in patients who have ever received lentiviral-based gene-edited immune cells manufactured by Pell Bio-Med Technology Co. Ltd. Such research initiatives in the field of gene delivery systems are anticipated to boost the market growth over the forecast period.

Various initiatives taken by the key market players such as product launches, expansion, and partnerships are expected to boost the market's growth during the forecast period. For instance, in June 2021, VIVEbiotech opened its new lentiviral vector manufacturing facilities in Spain, expanding the capacity for lentiviral vectors for use in cell and gene therapies. Such developments are expected to drive the market's growth over the forecast period.

However, the high cost of the treatment is expected to restrain the growth of the studied market over the forecast period.

Gene Delivery System Industry Segmentation

As per the scope of the report, gene delivery is the process of introducing foreign genetic material, such as DNA or RNA, into host cells. 

The Gene Delivery Systems Market is segmented by Delivery Systems (Viral Gene Delivery Systems, Non-viral Gene Delivery Systems, and Combined Hybrid Delivery Systems), Applications (Oncology, Infectious Diseases, Cardiovascular Disorders, Diabetes, Pulmonary Disorders, Other Applications), Route of Administration (Oral, Injectable, Nasal, and Other Routes of Administration), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (in USD million) for the above segments